ACTRN12612001175864
Completed
未知
A study involving early breast cancer patients upon completion of active treatment to determine their views on a pilot breast cancer survivorship care plan designed for a New Zealand context.
Regional Cancer Treatment Service, MidCentral Health DHB0 sites30 target enrollmentNovember 6, 2012
Overview
- Phase
- 未知
- Intervention
- Not specified
- Conditions
- Breast cancer
- Sponsor
- Regional Cancer Treatment Service, MidCentral Health DHB
- Enrollment
- 30
- Status
- Completed
- Last Updated
- 6 years ago
Overview
Brief Summary
No summary available.
Investigators
Eligibility Criteria
Inclusion Criteria
- •1\.Females or males with histologically diagnosed early breast cancer who have undergone surgery alone or just completed adjuvant chemotherapy and/or radiation therapy if this is required. Patients can be receiving adjuvant hormone therapy or adjuvant herceptin therapy.
- •2\.Age \>\=18 yrs.
- •3\.Able to read English proficiently.
- •4\.Willing and able to comply with all study requirements.
- •5\.Signed, written informed consent.
Exclusion Criteria
- •1\.Patients who do not have a histological breast cancer diagnosis.
- •2\.Patients with metastatic breast cancer.
- •3\.Patients still receiving adjuvant chemotherapy or radiation therapy.
- •4\.Life expectancy of less than 6 months.
- •5\.Presence of any psychological, familial, sociological or geographical condition potentially hampering compliance with the study protocol and follow\-up schedule, including alcohol dependence or drug abuse.
Outcomes
Primary Outcomes
Not specified
Similar Trials
Active, not recruiting
Phase 1
Pivotal study in breast cancer patients investigating efficacy and safety of LA-EP2006 and Neulasta®Breast CancerTherapeutic area: Diseases [C] - Cancer [C04]EUCTR2012-002039-28-ESSandoz GmbH308
Completed
Phase 3
A study to evaluate the Efficacy and Safety of LA-EP2006 and Neulasta® in patients with breast cancer.CTRI/2012/10/003065Sandoz GmbH302
Recruiting
Not Applicable
A study to estimate improvement in quality of life, cost effectiveness of radiotherapy in patients of breast cancer with bone metastases.Health Condition 1: null- Patients of breast cancer who have been newly diagnosed with bone metastases and who will be planned for palliative radiotherapyCTRI/2018/03/012317Tata Memorial Hospital
Recruiting
Phase 2
Pre-operative phase II trial for breast cancer with nivolumab in combination with novel IO (BELLINI trial)NL-OMON54814ederlands Kanker Instituut90
Active, not recruiting
Phase 1
Pre-operative study for breast cancer with nivolumab in combination with other therapyMedDRA version: 21.1Level: LLTClassification code 10006188Term: Breast cancer female NOSSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10006194Term: Breast cancer NOS stage ISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10006195Term: Breast cancer NOS stage IISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)MedDRA version: 20.0Level: LLTClassification code 10006196Term: Breast cancer NOS stage IIISystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)Therapeutic area: Diseases [C] - Cancer [C04]EUCTR2018-004188-30-NLKI-AV90